Loading organizations...
§ Private Profile · Hudson, MA, USA
Pharmaceutical company developing value-added medications by optimizing established drugs for cardiovascular unmet needs.
Auxilius Pharma is an early-stage pharmaceutical development company based in Boston and Saratoga Springs, New York, that creates value-added medications by optimizing established drugs for specific unmet medical needs. The company focuses primarily on cardiovascular health, with its lead asset, AUX-001, targeting chronic-stable angina pectoris, a condition affecting approximately 11 million Americans. By reformulating existing therapies currently available in the European Union for the United States market, the firm utilizes established clinical data to mitigate the high financial risks typically associated with novel drug discovery. To finance its ongoing research and clinical development programs, the enterprise successfully raised $1 million in seed funding through a round led by CofounderZone, with participation from AUGEBIT Closed Investment Fund and legal advisement from B2RLaw. Auxilius Pharma was officially founded in 2019 by co-founders Uwe Tigör and Jed Litwiniuk.
Auxilius Pharma has raised $1.0M across 1 funding round.
Auxilius Pharma has raised $1.0M in total across 1 funding round.
Auxilius Pharma has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 14, 2023 | $1M Seed | CofounderZone | — | Announced |
Auxilius Pharma has raised $1.0M in total across 1 funding round.
Auxilius Pharma's investors include CofounderZone.